APA (7th ed.) Citation

Morris, M. J., Castellano, D., Herrmann, K., de Bono, J. S., Shore, N. D., Chi, K. N., . . . Wilke, C. (2024). 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): A phase 3, randomised, controlled trial. Lancet, 404(10459), 1227. https://doi.org/10.1016/S0140-6736(24)01653-2

Chicago Style (17th ed.) Citation

Morris, Michael J., et al. "177Lu-PSMA-617 Versus a Change of Androgen Receptor Pathway Inhibitor Therapy for Taxane-naive Patients with Progressive Metastatic Castration-resistant Prostate Cancer (PSMAfore): A Phase 3, Randomised, Controlled Trial." Lancet 404, no. 10459 (2024): 1227. https://doi.org/10.1016/S0140-6736(24)01653-2.

MLA (9th ed.) Citation

Morris, Michael J., et al. "177Lu-PSMA-617 Versus a Change of Androgen Receptor Pathway Inhibitor Therapy for Taxane-naive Patients with Progressive Metastatic Castration-resistant Prostate Cancer (PSMAfore): A Phase 3, Randomised, Controlled Trial." Lancet, vol. 404, no. 10459, 2024, p. 1227, https://doi.org/10.1016/S0140-6736(24)01653-2.